Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 86.33
+2.05 (2.43%)
Oct 16, 2025, 5:35 PM CET
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€551,871
Profits / Employee
€110,114
Market Cap
102.55B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| Sartorius Stedim Biotech | 9,901 |
| bioMérieux | 14,754 |
| Eurofins Scientific SE | 62,696 |
| Ipsen | 5,358 |
| ABIVAX Société Anonyme | 69 |
| Virbac | 6,365 |
| emeis Société anonyme | 83,494 |
Sanofi News
- 9 hours ago - EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi - PRNewsWire
- 2 days ago - Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Benzinga
- 3 days ago - ITM Appoints Annette Breunig as Chief People Officer - GlobeNewsWire
- 7 days ago - Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out - Investor's Business Daily
- 8 days ago - Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy - Seeking Alpha
- 8 days ago - BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform - Business Wire
- 8 days ago - Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment - Nasdaq
- 8 days ago - Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors - GlobeNewsWire